| | |
| Clinical data | |
|---|---|
| Trade names | Acofide, others |
| Other names | YM-443, Z-338 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 84.21–85.95% |
| Metabolism | UGT1A8 and 1A9 (major) |
| Elimination half-life | 10.9–21.7 hours |
| Excretion | Feces (92.7%), urine (5.3%) [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30N4O5S |
| Molar mass | 450.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Acotiamide, sold under the brand names Acofide, [2] [3] and Dyspevict is a medication manufactured and approved in Japan and Russia [4] for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. [5] It acts as an acetylcholinesterase inhibitor.